Pravibismane - Microbion Corporation
Alternative Names: BisEDT Antimicrobial Gel; MBN-101Latest Information Update: 19 Nov 2024
Price :
$50 *
At a glance
- Originator Microbion Corporation
- Class Alkanes; Anti-infectives; Antibacterials; Foot disorder therapies; Organic sulfur compounds; Skin disorder therapies
- Mechanism of Action Bacterial biofilm inhibitors; Bacterial growth inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Bacterial infections; Diabetic foot ulcer
- Phase I Cystic fibrosis-associated respiratory tract infections; Nontuberculous mycobacterium infections
Most Recent Events
- 13 Nov 2024 Adverse events and pharmacodynamics data from a phase II trial in Diabetic foot ulcer released by Microbion
- 30 Jan 2024 Pravibismane - Microbion Corporation receives Orphan Drug status for Nontuberculous mycobacterium infections in USA
- 30 Jan 2024 Antimicrobial data from a preclinical trial in Nontuberculous mycobacterial infections released by Microbion Corporation